EGFR and non-small cell lung carcinoma: Modulating Bim transcription may not be the only mechanism by which aspirin overcomes osimertinib resistance in EGFR‐mutated NSCLC, and in‐depth clinical studies will continue to identify other potential markers linked to aspirin's beneficial effects.